ciprofloxacin has been researched along with docetaxel anhydrous in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ando, M; Katsumata, N; Mizuno, T; Mukai, H; Shimizu, C; Watanabe, T | 1 |
| Moreira, JN; Pinto, AC; Simões, S | 1 |
| Anami, S; Fujii, C; Kitada, N; Kondoh, M; Minegaki, T; Morita, S; Nishino, M; Takara, K; Watari, M; Yasuda, J | 1 |
1 review(s) available for ciprofloxacin and docetaxel anhydrous
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for ciprofloxacin and docetaxel anhydrous
| Article | Year |
|---|---|
[Equalization of breast cancer chemotherapy at general hospital( II )-evaluation of safety in FEC and TC regimens].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Ciprofloxacin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Hospitals, General; Humans; Japan; Middle Aged; Neutropenia; Taxoids | 2009 |
3 other study(ies) available for ciprofloxacin and docetaxel anhydrous
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
The outpatient management of low-risk febrile patients with neutropenia: risk assessment over the telephone.
Topics: Adult; Aged; Ambulatory Care; Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Ciprofloxacin; Clinical Trials, Phase II as Topic; Docetaxel; Doxorubicin; Feasibility Studies; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Japan; Middle Aged; Neoadjuvant Therapy; Neutropenia; Recombinant Proteins; Retrospective Studies; Risk Assessment; Taxoids; Telephone; Treatment Outcome | 2007 |
Ciprofloxacin sensitizes hormone-refractory prostate cancer cell lines to doxorubicin and docetaxel treatment on a schedule-dependent manner.
Topics: Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Ciprofloxacin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Antagonism; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Male; Prostatic Neoplasms; Taxoids; Time Factors | 2009 |